Patrick Soon-Shiong Net Worth

Patrick Soon-Shiong has an estimated net worth of $10.7 billion, according to Forbes Real-Time Billionaires, Patrick Soon-Shiong profile (figures as of October 20, 2026). That is up from $7 billion in 2019.

Patrick Soon-Shiong is a medical doctor, surgeon, researcher, and businessman in healthcare. He is best known for inventing Abraxane, a cancer drug used for lung, breast, and pancreatic cancer. Forbes places him in healthcare and describes him as self-made. His career mixed medicine with company building, and that combination made him a major figure in pharmaceuticals. He is also the owner and executive chairman of the Los Angeles Times and a minority owner of the Los Angeles Lakers.

His wealth came from building and selling drug companies, then launching new biotech businesses. Forbes says he sold American Pharmaceutical Partners in 2008 and Abraxis in 2010 for a combined $9.1 billion. He later took NantKwest public in 2015 and NantHealth public in 2016. Soon-Shiong also owns NantWorks, a group of health startups, and he bought the Los Angeles Times and San Diego Tribune for $500 million in 2018.

How Patrick Soon-Shiong built his fortune

Soon-Shiong made his name in medicine before turning that work into major businesses. Forbes says he invented Abraxane, which became a blockbuster because it worked well against pancreatic cancer. Earlier, he started companies that grew into American Pharmaceutical Partners and Abraxis. Those deals were the biggest drivers of his fortune. In 2008 and 2010, he sold those drug companies for a combined $9.1 billion, turning years of research and development into large exits.

He kept expanding after those sales. Soon-Shiong owns NantWorks, which Forbes describes as a network of health startups. He also brought more biotech firms to the public markets by taking NantKwest public in 2015 and NantHealth public in 2016. His interests go beyond biotech. Forbes says he has stakes in Tribune Publishing and the Los Angeles Lakers, and in June 2018 he bought the Los Angeles Times and San Diego Tribune for $500 million.

What Forbes says about his net worth

Forbes has tracked several swings in Soon-Shiong's fortune. Its World's Billionaires List estimated his net worth at $7 billion in 2019, $6.4 billion in 2020, $7.5 billion in 2021, $7.3 billion in 2022, $5.8 billion in 2023, $6.2 billion in 2024, $5.9 billion in 2025, and $10.5 billion in 2026. Those changes line up with the value of his holdings across pharmaceuticals, biotech, media, and sports.

The latest Forbes update is higher than its annual 2026 list. Forbes' real-time billionaires tracker put him at $10.7 billion in October 2026, and that is the current figure listed here. The facts behind that fortune still point to the same core sources: the earlier sales of American Pharmaceutical Partners and Abraxis, his ownership of NantWorks, and later public market exposure through NantKwest, NantHealth, and ImmunityBio.